SALLY STABLER, MD
Osteopathic Medicine at 16 Ave, Denver, CO

6528496, Mar 4, 2003

Feb 26, 2001

09/793214

Robert H. Allen - Denver CO 80206
Sally P. Stabler - Denver CO 80206

A01N 4304

514 52, 514249, 514345

A method for orally administering vitamin preparations is described which combine vitamin B (B , cobalamin) and folic acid (folate), with and without pyridoxine (B ), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative of B and/or folic acid deficiencies. Further, it is likely that a B deficiency may be present with a B or folate deficiency. The method of the invention is also for use in lowering serum HC, CT, MMA, or 2-MCA in patients with or at risk for neuropsychiatric, vascular, renal or hematologic diseases. The method of the present invention eliminates the costly and time consuming steps of distinguishing between vitamin deficiencies once a deficiency is found by measurement of serum metabolite levels. The present invention is of particular benefit to the populations at risk for elevated serum metabolite levels, such as the people over the age of 65, and populations that have or are at risk for neuropsychiatric, vascular, renal and hematologic diseases.

5563126, Oct 8, 1996

Dec 29, 1992

7/999499

Robert H. Allen - Englewood CO
Sally P. Stabler - Denver CO

Metabolite Laboratories - Denver CO

A61K 3170, A61K 31495, A61K 3144

514 52

A method for orally administering vitamin preparations is described which combine vitamin B. sub. 12 (B. sub. 12, cobalamin) and folic acid (folate), with and without pyridoxine (B. sub. 6), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative of B. sub. 12 and/or folic acid deficiencies. Further, it is likely that a B. sub. 6 deficiency may be present with a B. sub. 12 or folate deficiency. The method of the invention is also for use in lowering serum HC, CT, MMA, or 2-MCA in patients with or at risk for neuropsychiatric, vascular, renal or hematologic diseases. One embodiment of the invention is the use of a non-prescription formulation containing 2. 0 mg B. sub. 12 and 0. 4 mg folic acid, with and without 25 mg B. sub. 6.

6207651, Mar 27, 2001

Jan 26, 1998

9/012955

Robert H. Allen - Denver CO
Sally P. Stabler - Denver CO

Metabolite Laboratories - Denver CO

A61K31/70

514 52

A method for orally administering vitamin preparations is described which combine vitamin B. sub. 12 (B. sub. 12, cobalamin) and folic acid (folate), with and without pyridoxine (B. sub. 6), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative of B. sub. 12 and/or folic acid deficiencies. Further, it is likely that a B. sub. 6 deficiency may be present with a B. sub. 12 or folate deficiency. The method of the invention is also for use in lowering serum HC, CT, MMA, or 2-MCA in patients with or at risk for neuropsychiatric, vascular, renal or hematologic diseases. One embodiment of the invention is the use of a non-prescription formulation containing 2. 0 mg B. sub. 12 and 0. 4 mg folic acid, with and without 25 mg B. sub. 6.

2003021, Nov 13, 2003

Dec 4, 2002

10/309761

Robert Allen - Denver CO, US
Sally Stabler - Denver CO, US

A61K031/714, A61K031/525, A61K031/4415

514/052000, 514/251000, 514/350000

A method for orally administering vitamin preparations is described which combine vitamin B(B, cobalamin) and folic acid (folate), with and without pyridoxine (B), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative of Band/or folic acid deficiencies. Further, it is likely that a Bdeficiency may be present with a Bor folate deficiency. The method of the invention is also for use in lowering serum HC, CT, MMA, or 2-MCA in patients with or at risk for neuropsychiatric, vascular, renal or hematologic diseases. The method of the present invention eliminates the costly and time consuming steps of distinguishing between vitamin deficiencies once a deficiency is found by measurement of serum metabolite levels. The present invention is of particular benefit to the populations at risk for elevated serum metabolite levels, such as the people over the age of 65, and populations that have or are at risk for neuropsychiatric, vascular, renal and hematologic diseases.

5374560, Dec 20, 1994

Jul 10, 1991

7/727628

Robert H. Allen - Englewood CO
Sally P. Stabler - Denver CO
John Lindenbaum - New York NY

The University of Colorado, Inc. - Boulder CO

G01N 3350, G01N 3368, G01N 3004, G01N 134

436129

A method for screening and distinguishing between cobalamin deficiency and folic acid deficiency by relating elevated levels of cystathionine to cobalamin or folic acid deficiency and relating elevated levels of 2-methylcitric acid to cobalamin deficiency but not folic acid deficiency. The methods can be used alone or in combination with other methods for detecting and distinguishing between cobalamin deficiency and folic acid deficiency.

2003021, Nov 20, 2003

Dec 4, 2002

10/309752

Robert Allen - Denver CO, US
Sally Stabler - Denver CO, US

A61K031/714, A61K031/525

514/052000, 514/251000

A method for orally administering vitamin preparations is described which combine vitamin B(B, cobalamin) and folic acid (folate), with and without pyridoxine (B), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative of Band/or folic acid deficiencies. Further, it is likely that a Bdeficiency may be present with a Bor folate deficiency. The method of the invention is also for use in lowering serum HC, CT, MMA, or 2-MCA in patients with or at risk for neuropsychiatric, vascular, renal or hematologic diseases. The method of the present invention eliminates the costly and time consuming steps of distinguishing between vitamin deficiencies once a deficiency is found by measurement of serum metabolite levels. The present invention is of particular benefit to the populations at risk for elevated serum metabolite levels, such as the people over the age of 65, and populations that have or are at risk for neuropsychiatric, vascular, renal and hematologic diseases.

2003022, Dec 4, 2003

Dec 4, 2002

10/309802

Robert Allen - Denver CO, US
Sally Stabler - Denver CO, US

A61K031/714, A61K031/525

514/052000, 514/251000

A method for orally administering vitamin preparations is described which combine vitamin B(B, cobalamin) and folic acid (folate), with and without pyridoxine (B), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative of Band/or folic acid deficiencies. Further, it is likely that a Bdeficiency may be present with a Bor folate deficiency. The method of the invention is also for use in lowering serum HC, CT, MMA, or 2-MCA in patients with or at risk for neuropsychiatric, vascular, renal or hematologic diseases. The method of the present invention eliminates the costly and time consuming steps of distinguishing between vitamin deficiencies once a deficiency is found by measurement of serum metabolite levels. The present invention is of particular benefit to the populations at risk for elevated serum metabolite levels, such as the people over the age of 65, and populations that have or are at risk for neuropsychiatric, vascular, renal and hematologic diseases.

5438017, Aug 1, 1995

Oct 14, 1992

7/960783

Robert H. Allen - Englewood CO
Sally P. Stabler - Denver CO

The University of Colorado Foundation, Inc. - CO

G01N 2400, C12Q 100

436 89

Improved methods for the GC/MS analysis of sulfhydryl amino acids and methylmalonic acids in samples of body fluids are provided. Additionally a method for combined assay of sulfhydryl amino acids particularly total homocysteine and combined creatine/creatinine levels in samples of body fluids provided. The information provided by the methods described is useful in the detection of the presence of cobalamin or folate deficiencies in individuals and in distinguishing between the two deficiencies.